{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:40:02Z","timestamp":1756377602697,"version":"3.44.0"},"reference-count":42,"publisher":"BMJ","issue":"5","funder":[{"DOI":"10.13039\/100000054","name":"National Cancer Institute","doi-asserted-by":"publisher","award":["K08 CA248473"],"award-info":[{"award-number":["K08 CA248473"]}],"id":[{"id":"10.13039\/100000054","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["bmj.com"],"crossmark-restriction":true},"short-container-title":["BMJ Case Rep"],"accepted":{"date-parts":[[2024,4,12]]},"published-print":{"date-parts":[[2024,5]]},"abstract":"<jats:p>A woman in her 60s was diagnosed with a metastatic, unresectable rare histological type of liver cancer; combined hepatocellular cholangiocarcinoma. She had palliative chemotherapy, initially with gemcitabine and cisplatin, and then with oxaliplatin, L-folinic acid and fluorouracil. Both treatment strategies demonstrated disease progression, and somatic mutation profiling revealed no actionable mutations. The patient was started on immuno-oncology (IO) with nivolumab and ipilimumab, followed by maintenance nivolumab. She has achieved a sustained ongoing partial response since the start of this therapy for at least 12 months. The outcome in this patient is in keeping with the growing evidence of the role that IO agents have in metastatic biliary tract cancer and also serves to highlight their importance in mixed histology liver tumours.<\/jats:p>","DOI":"10.1136\/bcr-2023-255003","type":"journal-article","created":{"date-parts":[[2024,5,2]],"date-time":"2024-05-02T12:56:00Z","timestamp":1714654560000},"page":"e255003","update-policy":"https:\/\/doi.org\/10.1136\/crossmarkpolicy","source":"Crossref","is-referenced-by-count":1,"title":["Efficacy of dual checkpoint inhibitors in a patient with a mixed hepatocellular cholangiocarcinoma"],"prefix":"10.1136","volume":"17","clinical-trial-number":[{"clinical-trial-number":"nct02923934","registry":"10.18810\/clinical-trials-gov"},{"clinical-trial-number":"nct02923934","registry":"10.18810\/clinical-trials-gov"}],"author":[{"given":"Santiago","family":"Sucre","sequence":"first","affiliation":[{"name":"Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Andrea","family":"Bullock","sequence":"additional","affiliation":[{"name":"Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0905-7583","authenticated-orcid":false,"given":"Mary Linton","family":"Peters","sequence":"additional","affiliation":[{"name":"Medical Oncology, Beth Israel Deaconess Medical Center, Boston, Massachusetts, USA"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"239","published-online":{"date-parts":[[2024,5,2]]},"reference":[{"key":"2025082803044223000_17.5.e255003.1","first-page":"7","article-title":"Cancer statistics","volume":"72","author":"Siegel","year":"2022","journal-title":"CA A Cancer J Clinicians"},{"key":"2025082803044223000_17.5.e255003.2","doi-asserted-by":"crossref","first-page":"4","DOI":"10.1002\/hep.31288","article-title":"Epidemiology of hepatocellular carcinoma","volume":"73 Suppl 1","author":"McGlynn","year":"2021","journal-title":"Hepatology"},{"key":"2025082803044223000_17.5.e255003.3","doi-asserted-by":"publisher","DOI":"10.1053\/jhep.2001.25087"},{"key":"2025082803044223000_17.5.e255003.4","doi-asserted-by":"publisher","DOI":"10.1016\/j.jhep.2003.11.030"},{"key":"2025082803044223000_17.5.e255003.5","article-title":"Incidence of cholangiocarcinoma in the USA from 2001 to 2015: a US cancer statistics analysis of 50 states","volume":"11","author":"Patel","year":"2019","journal-title":"Cureus"},{"key":"2025082803044223000_17.5.e255003.6","doi-asserted-by":"crossref","first-page":"101","DOI":"10.21037\/hbsn.2017.01.02","article-title":"Epidemiology and risk factors: intrahepatic cholangiocarcinoma","volume":"6","author":"Gupta","year":"2017","journal-title":"Hepatobiliary Surg Nutr"},{"key":"2025082803044223000_17.5.e255003.7","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.3348\/kjr.2020.0091","article-title":"Combined hepatocellular-cholangiocarcinoma: changes in the 2019 World Health Organization histological classification system and potential impact on imaging-based diagnosis","volume":"21","author":"Kim","year":"2020","journal-title":"Korean J Radiol"},{"key":"2025082803044223000_17.5.e255003.8","doi-asserted-by":"publisher","DOI":"10.1093\/carcin\/bgs208"},{"key":"2025082803044223000_17.5.e255003.9","doi-asserted-by":"publisher","DOI":"10.1097\/PAS.0b013e31827332b0"},{"key":"2025082803044223000_17.5.e255003.10","doi-asserted-by":"publisher","DOI":"10.4254\/wjh.v2.i12.419"},{"key":"2025082803044223000_17.5.e255003.11","doi-asserted-by":"crossref","DOI":"10.3390\/cancers12040794","article-title":"Treatment of combined hepatocellular and cholangiocarcinoma","volume":"12","author":"Leoni","year":"2020","journal-title":"Cancers (Basel)"},{"key":"2025082803044223000_17.5.e255003.12","doi-asserted-by":"crossref","first-page":"e1774","DOI":"10.1002\/onco.13893","article-title":"Long-term survival of combined hepatocellular-cholangiocarcinoma: a nationwide study","volume":"26","author":"Chen","year":"2021","journal-title":"Oncologist"},{"key":"2025082803044223000_17.5.e255003.13","doi-asserted-by":"crossref","first-page":"448","DOI":"10.37349\/etat.2021.00056","article-title":"A review of molecularly targeted therapy in biliary tract carcinoma: what is the next step?","volume":"2","author":"Aimar","year":"2021","journal-title":"Explor Target Antitumor Ther"},{"key":"2025082803044223000_17.5.e255003.14","doi-asserted-by":"crossref","first-page":"565","DOI":"10.1001\/jamasurg.2013.5137","article-title":"Treatment and prognosis for patients with intrahepatic cholangiocarcinoma","volume":"149","author":"Mavros","year":"2014","journal-title":"JAMA Surg"},{"key":"2025082803044223000_17.5.e255003.15","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa0908721"},{"key":"2025082803044223000_17.5.e255003.16","doi-asserted-by":"crossref","first-page":"378","DOI":"10.1200\/JCO.2022.40.4_suppl.378","article-title":"A phase 3 randomized, double-blind, placebo-controlled study of Durvalumab in combination with Gemcitabine plus cisplatin (Gemcis) in patients (PTS) with advanced biliary tract cancer (BTC): TOPAZ-1","volume":"40","author":"Oh","year":"2022","journal-title":"JCO"},{"key":"2025082803044223000_17.5.e255003.17","unstructured":"Benson A , et al . NCCN guidelines version 2. 2023 biliary tract cancers [NCCN]. 2023. Available: https:\/\/www.nccn.org\/guidelines\/category_1 [Accessed 26 Sep 2023]."},{"key":"2025082803044223000_17.5.e255003.18","doi-asserted-by":"publisher","DOI":"10.1016\/S1470-2045(21)00027-9"},{"key":"2025082803044223000_17.5.e255003.19","doi-asserted-by":"crossref","first-page":"75","DOI":"10.1002\/hep.31410","article-title":"The tumor microenvironment in cholangiocarcinoma progression","volume":"73 Suppl 1","author":"Fabris","year":"2021","journal-title":"Hepatology"},{"key":"2025082803044223000_17.5.e255003.20","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/s41572-020-00240-3","article-title":"Hepatocellular carcinoma","volume":"7","author":"Llovet","year":"2021","journal-title":"Nat Rev Dis Primers"},{"key":"2025082803044223000_17.5.e255003.21","doi-asserted-by":"crossref","first-page":"6445","DOI":"10.3390\/curroncol29090507","article-title":"A review of current and emerging therapies for advanced hepatocellular carcinoma","volume":"29","author":"Singh","year":"2022","journal-title":"Curr Oncol"},{"key":"2025082803044223000_17.5.e255003.22","doi-asserted-by":"crossref","DOI":"10.1001\/jamaoncol.2020.4564","article-title":"Efficacy and safety of Nivolumab plus Ipilimumab in patients with advanced hepatocellular carcinoma previously treated with sorafenib","volume":"6","author":"Yau","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025082803044223000_17.5.e255003.23","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1915745"},{"key":"2025082803044223000_17.5.e255003.24","doi-asserted-by":"crossref","unstructured":"Abou-Alfa GK , Lau G , Kudo M , et al . Tremelimumab plus durvalumab in unresectable hepatocellular carcinoma. NEJM Evidence 2022;1. doi:10.1056\/EVIDoa2100070","DOI":"10.1056\/EVIDoa2100070"},{"key":"2025082803044223000_17.5.e255003.25","doi-asserted-by":"crossref","first-page":"310","DOI":"10.1007\/s00261-013-0069-6","article-title":"Combined hepatocellular-cholangiocarcinoma: what the radiologist needs to know about biphenotypic liver carcinoma","volume":"39","author":"Shetty","year":"2014","journal-title":"Abdom Imaging"},{"key":"2025082803044223000_17.5.e255003.26","doi-asserted-by":"crossref","DOI":"10.3389\/fonc.2020.570958","article-title":"Update on the genetics of and systemic therapy options for combined hepatocellular cholangiocarcinoma","volume":"10","author":"Azizi","year":"2020","journal-title":"Front Oncol"},{"key":"2025082803044223000_17.5.e255003.27","doi-asserted-by":"crossref","first-page":"1405","DOI":"10.1001\/jamaoncol.2020.2814","article-title":"Evaluation of combination nivolumab and Ipilimumab immunotherapy in patients with advanced biliary tract cancers","volume":"6","author":"Klein","year":"2020","journal-title":"JAMA Oncol"},{"key":"2025082803044223000_17.5.e255003.28","doi-asserted-by":"crossref","first-page":"1371","DOI":"10.1016\/j.jfma.2022.03.017","article-title":"Immune checkpoint inhibitors for hepatocellular carcinoma \u2013 a game changer in treatment landscape","volume":"121","author":"Liu","year":"2022","journal-title":"J Formos Med Assoc"},{"key":"2025082803044223000_17.5.e255003.29","doi-asserted-by":"crossref","DOI":"10.3390\/cancers13071569","article-title":"Immunotherapy in advanced biliary tract cancers","volume":"13","author":"Boil\u00e8ve","year":"2021","journal-title":"Cancers (Basel)"},{"key":"2025082803044223000_17.5.e255003.30","doi-asserted-by":"publisher","DOI":"10.1016\/j.suc.2020.02.013"},{"key":"2025082803044223000_17.5.e255003.31","unstructured":"Benson A , et al . NCCN guidelines version 3. 2022 hepatobiliary cancers [NCCN]. 2022. Available: https:\/\/www.nccn.org\/guidelines\/category_1"},{"key":"2025082803044223000_17.5.e255003.32","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2147\/JHC.S159805","article-title":"Combined hepatocellular cholangiocarcinoma (CHCC-CC): an update of genetics, molecular biology, and therapeutic interventions","volume":"6","author":"Stavraka","year":"2019","journal-title":"J Hepatocell Carcinoma"},{"key":"2025082803044223000_17.5.e255003.33","first-page":"199","article-title":"Management of combined hepatocellular-cholangiocarcinoma: a case report and literature review","volume":"5","author":"Chi","year":"2012","journal-title":"Gastrointest Cancer Res"},{"key":"2025082803044223000_17.5.e255003.34","doi-asserted-by":"crossref","DOI":"10.1200\/JCO.2021.39.15_suppl.e16194","article-title":"Efficacy of immunotherapy in hepatocholangiocarcinoma (HCC-CC): proof of concept","volume":"39","author":"Diab","year":"2021","journal-title":"JCO"},{"key":"2025082803044223000_17.5.e255003.35","unstructured":"Klein O , Cebon J . A phase II trial of Ipilimumab and Nivolumab for the treatment of rare cancers. 2017. Available: https:\/\/clinicaltrials.gov\/ct2\/show\/NCT02923934"},{"key":"2025082803044223000_17.5.e255003.36","doi-asserted-by":"publisher","DOI":"10.1200\/JCO.19.00318"},{"key":"2025082803044223000_17.5.e255003.37","doi-asserted-by":"publisher","DOI":"10.1634\/theoncologist.2019-0299"},{"key":"2025082803044223000_17.5.e255003.38","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1606774"},{"key":"2025082803044223000_17.5.e255003.39","doi-asserted-by":"publisher","DOI":"10.1056\/NEJMoa1500596"},{"key":"2025082803044223000_17.5.e255003.40","doi-asserted-by":"publisher","DOI":"10.1158\/1535-7163.MCT-17-0386"},{"key":"2025082803044223000_17.5.e255003.41","doi-asserted-by":"crossref","DOI":"10.1016\/j.iotech.2022.100071","article-title":"Multimodal predictors for precision immunotherapy","volume":"14","author":"Roelofsen","year":"2022","journal-title":"Immunooncol Technol"},{"key":"2025082803044223000_17.5.e255003.42","doi-asserted-by":"crossref","DOI":"10.1186\/s40425-016-0153-x","article-title":"PD-L1 biomarker testing for non-small cell lung cancer: truth or fiction?","volume":"4","author":"Grigg","year":"2016","journal-title":"J Immunother Cancer"}],"container-title":["BMJ Case Reports"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1136\/bcr-2023-255003","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,8,28]],"date-time":"2025-08-28T10:04:51Z","timestamp":1756375491000},"score":1,"resource":{"primary":{"URL":"https:\/\/casereports.bmj.com\/lookup\/doi\/10.1136\/bcr-2023-255003"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,5]]},"references-count":42,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2024,5,2]]},"published-print":{"date-parts":[[2024,5]]}},"alternative-id":["10.1136\/bcr-2023-255003"],"URL":"https:\/\/doi.org\/10.1136\/bcr-2023-255003","relation":{},"ISSN":["1757-790X"],"issn-type":[{"type":"electronic","value":"1757-790X"}],"subject":[],"published":{"date-parts":[[2024,5]]}}}